Literature DB >> 16680743

Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis.

Nadeem Ikhlaque1, Vidya Seshadri, Satheesh Kathula, Michael A Baumann.   

Abstract

BACKGROUND: Deep venous thrombosis (DVT) is a common complication of thalidomide treatment. There is little information to guide clinicians in selecting effective preventive treatments and physician practice varies. We sought to determine whether prophylactic anticoagulation with warfarin prevents DVT related to thalidomide treatment.
METHODS: We reviewed the records of 131 patients receiving thalidomide for a variety of indications. Fifty-five patients were prescribed warfarin with the intent of preventing DVT. Thirty-seven patients received warfarin at a dose of 1-2 mg per day (low dose) and 18 received a dose intended to raise the INR to 2-3 (high dose).
RESULTS: Twenty-one of the 131 patients developed venous thrombosis during thalidomide treatment. Eighteen of the 76 patients (23.7%) who were not prescribed prophylactic anticoagulation developed DVT compared to 3 of the 55 patients (5.5%) who were prescribed any dose of prophylactic warfarin (P = 0.010). Only 1 of the 37 patients who received low-dose warfarin developed DVT (P = 0.011). Bleeding complications occurred in 4 patients, all of whom were receiving high-dose warfarin.
CONCLUSION: Prophylactic anticoagulation with warfarin reduces the risk of thrombosis during thalidomide treatment. Low-dose warfarin may be as effective as higher dose treatment and may result in fewer bleeding complications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16680743     DOI: 10.1002/ajh.20625

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  Thromboprophylaxis in multiple myeloma: is the evidence there?

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren
Journal:  Expert Rev Anticancer Ther       Date:  2012-03       Impact factor: 4.512

Review 2.  Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.

Authors:  Gary H Lyman
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

3.  A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

Authors:  Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas
Journal:  J Neurooncol       Date:  2008-07-26       Impact factor: 4.130

4.  Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.

Authors:  Vinay K Puduvalli; Pierre Giglio; Morris D Groves; Kenneth R Hess; Mark R Gilbert; Srikanth Mahankali; Edward F Jackson; Victor A Levin; Charles A Conrad; Sigmund H Hsu; Howard Colman; John F de Groot; Melesa G Ritterhouse; Sandra E Ictech; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2008-02-26       Impact factor: 12.300

5.  Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Authors:  Kenneth C Anderson; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jason C Chandler; Caitlin Costello; Benjamin Djulbegovic; Henry C Fung; Cristina Gasparetto; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Adetola Kassim; Amrita Y Krishnan; Shaji K Kumar; Michaela Liedtke; Matthew Lunning; Noopur Raje; Seema Singhal; Clayton Smith; George Somlo; Keith Stockerl-Goldstein; Steven P Treon; Donna Weber; Joachim Yahalom; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2015-11       Impact factor: 11.908

Review 6.  Therapeutic effects of thalidomide in hematologic disorders: a review.

Authors:  Miao Xu; Yu Hou; Lei Sheng; Jun Peng
Journal:  Front Med       Date:  2013-07-15       Impact factor: 9.927

7.  Anticoagulation in pulmonary arterial hypertension: a decision analysis.

Authors:  Arun Jose; Mark H Eckman; Jean M Elwing
Journal:  Pulm Circ       Date:  2019-12-23       Impact factor: 3.017

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.